Please login to the form below

Not currently logged in
Email:
Password:

US pharma

This page shows the latest US pharma news and features for those working in and with pharma, biotech and healthcare.

AZ taps Ionis for another drug, this time in NASH

AZ taps Ionis for another drug, this time in NASH

AZ taps Ionis for another drug, this time in NASH. Will acquire the US pharma group’s antisense drug in a deal valued up to $330m. ... and an untapped pharma market as there are as yet no approved treatments.

Latest news

  • Sun Pharma passes milestone with novel psoriasis drug approval Sun Pharma passes milestone with novel psoriasis drug approval

    Sun Pharma passes milestone with novel psoriasis drug approval. Ilumya will treat adults with a moderate-to-severe form of the skin condition. ... IL-23-selective follow-up Tremfya (guselkumab) as well as three IL-17 inhibitors - Novartis’ Cosentyx

  • Otsuka rewards digital health startup NeuroFlow Otsuka rewards digital health startup NeuroFlow

    Otsuka rewards digital health startup NeuroFlow. Mental illness tech platform wins the pharma firm's US pitch challenge. ... Digital inspiration for pharma on mobile, social media, strategy, best practice, regulations and more.

  • Fresenius says Akorn investigation could affect takeover Fresenius says Akorn investigation could affect takeover

    Fresenius Kabi says its $4.3bn deal to acquire US generic drugmaker Akorn Pharma could be scuppered by an FDA probe of the generic drug manufacturer. ... period of 2016, with the declines all coming from the prescription pharma business.

  • BMS’ Opdivo plus Yervoy aces phase III trial BMS’ Opdivo plus Yervoy aces phase III trial

    If the combo is approved however, the US pharma firm could be put in a strong position to take on Keytruda, which is already dominating the cancer immunotherapies market. ... the pharma group.

  • Novartis gets speedy reviews for new Kymriah filings Novartis gets speedy reviews for new Kymriah filings

    In the US, the Swiss pharma firm gets a priority review for Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ... The cell-based cancer immunotherapy was approved in the US

More from news
Approximately 7 fully matching, plus 468 partially matching documents found.

Latest Intelligence

  • A new era of smart pharma A new era of smart pharma

    A new era of smart pharma. How smarter pharmaceuticals and pharmacovigilance are transforming healthcare. ... Pharma companies are having to adapt and innovate to keep pace with the vast changes brought about by digital technology.

  • Six degrees of participation Six degrees of participation

    The era of Participatory Medicine - aka collaborative care or shared decision-making - is upon us, and fittingly for pharma, it’s the taking part that counts. ... UK, as well as the Head of Digital and therapeutic heads from within the pharma client

  • Health on instalment Health on instalment

    Health on instalment. Can US-style financial engineering underwrite ultra-expensive gene therapies? ... Given the animus that exists among US pharma stakeholders, reactions so far have been remarkably conciliatory.

  • Pharma deals continue to slide Pharma deals continue to slide

    Are deals being delayed or prevented by macroeconomic factors? Pfizer and some other big pharma companies are using uncertainty about US tax reform and Brexit and high company valuations as reasons ... 1, 410 (upfront 80). WuXi Biologics and Gloria

  • Macron, Merkel and May: implications of the 2017 elections for the life science industry Macron, Merkel and May: implications of the 2017 elections for the life science industry

    Being realistic, securing free trade deals with major economies such as the US, Japan and China could take a decade or more.

More from intelligence
Approximately 0 fully matching, plus 41 partially matching documents found.

Latest appointments

  • Targovax appoints Michael Bogenstaetter as chief business officer Targovax appoints Michael Bogenstaetter as chief business officer

    Øystein Soug, chief executive officer of Targovax, said: “Bogenstaetter’s extensive experience of business development and corporate strategy in the biotech and pharma industry will be indispensable to us.”.

  • Lighthouse Medical Communications appoints Andy Willmer as managing director Lighthouse Medical Communications appoints Andy Willmer as managing director

    Lucid Group subsidiary Lighthouse Medical Communications US has appointed Andy Willmer to head up its operations. ... Dennis O’Brien, CEO and co-founder of  Lucid, said: “Andy is a great fit with the team – and his history and experience in US and

  • Envigo appoints Lizanne Muller as president, EMEA operations Envigo appoints Lizanne Muller as president, EMEA operations

    Envigo appoints Lizanne Muller as president, EMEA operations. And Craig Boyd joins from Mayne Pharma as chief commercial officer. ... He has more than 20 years’experience in various global pharmaceutical markets and was previously executive vice

  • XenoGesis appoints business development consultant XenoGesis appoints business development consultant

    XenoGesis appoints business development consultant. Sabrina Mogle will spearhead CRO’ s US growth. ... Bringing expertise in business and corporate development in the biotech and pharma industries, Mogle will spearhead XenoGesis' US business

  • Natasha Giordano joins PLx Pharma Natasha Giordano joins PLx Pharma

    Natasha Giordano joins PLx Pharma. She replaces Ronald Zimmerman as president and chief executive officer. ... Giordano has also been appointed to the US specialty pharma company's board of directors, of which her predecessor Ronald Zimmerman will remain

More from appointments
Approximately 0 fully matching, plus 39 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics